Fei-Da Wu

机构：Nanjing Medical University

发表论文 4 篇 · 总被引 9 次 · h-index 2

代表论文

• Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma (2024 · World Journal of Gastrointestinal Oncology · 被引 7)
• A multifunctional hydrogel for inhibiting metastasis and recurrence of hepatocellular carcinoma via inflammation alleviation, metabolism regulation, and immune activation (2026 · Chemical Engineering Journal · 被引 2)
• A sub-cluster of cancer cells indicates poor prognosis in advanced hepatocellular carcinoma (2025 · Chinese Clinical Oncology)
• Validation of the CRAFITY score for predicting prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization combined with systemic therapy (2024 · Journal of interventional medicine)